Dendrite acquires Optas in $12 million deal

Pharma sales force effectiveness firm Dendrite announced that it has acquired relationship marketing firm Optas. The acquisition is valued at $12 million and will be funded by cash, Dendrite said in a statement.
Optas will be rebranded as "Optas: A Divison of Dendrite International."
A Dendrite spokeswoman told MM&M that no jobs will be eliminated as a result of the deal and key management posts on both sides of the deal will remain the same for the foreseeable future.
"Our combined offering will enable pharma companies to reach physicians and patients with consistent messaging and campaigns driven by deep patient and physician knowledge," said Stephen Smith, chief executive of Optas, in a statement.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.